Sapient Capital LLC Buys New Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Sapient Capital LLC purchased a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 10,146 shares of the biotechnology company's stock, valued at approximately $978,000.

Other hedge funds also recently made changes to their positions in the company. Montag A & Associates Inc. bought a new position in Sarepta Therapeutics in the 3rd quarter valued at approximately $30,000. Cary Street Partners Investment Advisory LLC raised its holdings in Sarepta Therapeutics by 154.0% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company's stock worth $31,000 after purchasing an additional 154 shares during the last quarter. KB Financial Partners LLC bought a new position in Sarepta Therapeutics during the 1st quarter worth approximately $36,000. Qube Research & Technologies Ltd bought a new position in Sarepta Therapeutics during the 3rd quarter worth approximately $33,000. Finally, Ossiam bought a new position in Sarepta Therapeutics during the 1st quarter worth approximately $105,000. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Stock Down 1.3 %

NASDAQ SRPT traded down $1.58 during mid-day trading on Friday, hitting $122.87. The company's stock had a trading volume of 656,117 shares, compared to its average volume of 590,725. The company's 50 day simple moving average is $127.46 and its 200 day simple moving average is $110.49. Sarepta Therapeutics, Inc. has a twelve month low of $55.25 and a twelve month high of $159.89. The company has a current ratio of 3.95, a quick ratio of 3.45 and a debt-to-equity ratio of 1.32. The firm has a market capitalization of $11.54 billion, a price-to-earnings ratio of -20.08 and a beta of 0.94.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.50. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The business had revenue of $396.80 million during the quarter, compared to the consensus estimate of $387.18 million. During the same quarter last year, the firm posted ($1.24) EPS. Sarepta Therapeutics's revenue was up 53.6% compared to the same quarter last year. Analysts anticipate that Sarepta Therapeutics, Inc. will post 2.14 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on SRPT shares. TheStreet upgraded shares of Sarepta Therapeutics from a "d" rating to a "c-" rating in a report on Monday, March 4th. Cantor Fitzgerald restated a "neutral" rating and set a $128.00 price target on shares of Sarepta Therapeutics in a report on Thursday, February 29th. Mizuho raised their price target on shares of Sarepta Therapeutics from $130.00 to $145.00 and gave the stock a "buy" rating in a report on Wednesday, February 14th. Citigroup raised their price target on shares of Sarepta Therapeutics from $160.00 to $172.00 and gave the stock a "buy" rating in a report on Thursday, February 29th. Finally, Royal Bank of Canada raised their price target on shares of Sarepta Therapeutics from $151.00 to $157.00 and gave the stock an "outperform" rating in a report on Thursday, February 29th. Four analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $158.38.

Insider Activity at Sarepta Therapeutics

In related news, Director Stephen Mayo sold 3,135 shares of Sarepta Therapeutics stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $122.96, for a total value of $385,479.60. Following the completion of the sale, the director now owns 6,621 shares of the company's stock, valued at approximately $814,118.16. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Sarepta Therapeutics news, Director Stephen Mayo sold 3,135 shares of Sarepta Therapeutics stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $122.96, for a total transaction of $385,479.60. Following the transaction, the director now directly owns 6,621 shares of the company's stock, valued at approximately $814,118.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Ian Michael Estepan sold 1,200 shares of Sarepta Therapeutics stock in a transaction on Friday, March 1st. The stock was sold at an average price of $128.30, for a total transaction of $153,960.00. Following the transaction, the chief financial officer now directly owns 39,114 shares in the company, valued at $5,018,326.20. The disclosure for this sale can be found here. In the last 90 days, insiders sold 22,096 shares of company stock valued at $2,739,419. 7.40% of the stock is owned by company insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.